Project Grant R01AI178776

Award Date 8/9/24
Completion Date 7/31/25
Dollars Obligated $1.5M
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Notre Dame, IN 46556, USA
Similar Awards
This $780,162 Project Grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases will fund research at Old Dominion University from August 2022 through July 2026 exploring the role of nutrient and stress sensing in regulating Clostridioides difficile physiology and behavior within the host. The research aims to determine how the stringent response regulates disease-relevant bacterial processes and characterize enzymes that mediate alarmone metabolism...
This $502,500 project grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award will fund research to elucidate the molecular mechanisms underlying ferrosome organelle biogenesis in the bacterium Clostridioides difficile, which is a leading cause of antibiotic-associated intestinal infections. The research aims to define how the ferrosome system enables C. difficile to adapt to iron...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $521,030 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of North Carolina at Chapel Hill to define the interplay between stochastic and regulatory mechanisms underlying the heterogeneous expression of flagella and toxins in Clostridioides difficile. The research aims to provide mechanistic insights into how C. difficile controls the production of key virulence factors and the...
This $894,552 project grant from the National Institutes of Health's National Institute of Allergy and Infectious Diseases Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research at the University of Nevada, Las Vegas to probe the effect of a high-fat/high-protein diet on Clostridioides difficile infection. Specifically, the researchers will examine how such a diet impacts inflammation, intestinal permeability, and the gut microbiome before and after antibiotic...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $661,693 to The University of Iowa to conduct research on defining the structure and function of a new family of peptidoglycan crosslinking enzymes in Clostridioides difficile, a leading cause of hospital-acquired infectious diarrhea. The primary objectives are to: (I) determine the structure and catalytic mechanism of the VanW domain in...
This federal Project Grant award of $261,492.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to elucidate the epigenetic regulation of sporulation in the pathogenic bacterium Clostridioides difficile. The research aims to identify specific DNA methylation sites that mediate the epigenetic control of sporulation, which is critical for the bacterium's ability to persist and cause...
The University of Notre Dame DU Lac's Notre Dame Research Division, doing business as the Office of Research, received a $471,006.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The 3-year grant, awarded on September 15, 2023, supports a bench-bedside-bidirectional investigation of a new combinatorial immunotherapy strategy to treat platinum-resistant penile cancer. As a leading research university, the University...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $222,852 to support research into the regulation of virulence factors in the pathogenic bacterium Clostridioides difficile. The primary objective is to identify and annotate Rho, NusA, and NusG dependent transcriptional terminators in C. difficile to understand how these regulatory factors influence the...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel probiotic yeast-based immunotherapy to prevent the transmission of Clostridioides difficile (C. difficile) infections. The $511,553 award will fund research to identify and screen neutralizing antibodies against the C. difficile surface protein CWP84, which is critical for bacterial...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $682,237 Project Grant to Villanova University under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support "The Development of Novel Disinfectants to Overcome Bacterial Resistance." The grant, which runs from July 22, 2024 to June 30, 2027, will fund research activities focused on developing new disinfectant formulations capable of overcoming increasing bacterial resistance to existing...

The University of Notre Dame DU Lac was awarded a $1,541,024 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant, titled "Spore Germination Pathway in Clostridioides Difficile and Its Pharmacological Intervention," aims to elucidate the process of spore germination in Clostridioides difficile, a deadly anaerobic bacterium that causes recurrent infections in patients treated with broad-spectrum antibiotics. The research project has three specific aims: 1) to further understand the details of the spore-germination pathway, 2) to demonstrate that inhibition of spore germination is key to preventing recurrence of C. difficile infection, and 3) to develop pharmacological interventions to inhibit spore germination and interrupt the cycle of recurrent infections. This research has the potential to address a significant public health challenge, as C. difficile infection is the deadliest of the five bacterial urgent threats in the United States.

Generated 7/1/25, 3:30 AM